Granulomatosis With Polyangiitis (Wegener's)
Also known as: Granulomatosis With Polyangitis / Granulomatosis With Polyangiitis (Wegener's Disease) / Wegener Granulomatosis / Wegener's Granulomatosis / Granulomatosis With Polyangiitis / Wegener Granulomatosis (WG) / Wegener’s Granulomatosis / Granulomatosis With Polyangiitis (GPA) / Granulomatosis, Wegener's / Polyangiitis, Granulomatosis With / Wegeners Granulomatosis / Granulomatosis With Polyangiitis (Wegener's Granulomatosis) / Wegeners Granulomatosis (Granulomatosis With Polyangiitis) / Granulomatosis With Polyangiitis (Wegener's) (GPA) / Wegener's granulomatosis without renal involvement / Granulomatous polyangiitis / Wegener's granulomatosis (disorder)
| Drug | Drug Name | Drug Description |
|---|---|---|
| DB15011 | Avacopan | An orally bioavailable complement 5a receptor (C5aR) antagonist for the treatment of severe anti-neutrophil cytoplasmic (auto)antibody (ANCA)-associated vasculitis. |
| DB00073 | Rituximab | A monoclonal anti-CD20 antibody used to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia, Wegener's granulomatosis, pemphigus vulgaris, and rheumatoid arthritis. |
| Drug | Drug Name | Target | Type |
|---|---|---|---|
| DB15011 | Avacopan | C5a anaphylatoxin chemotactic receptor 1 | target |
| DB15011 | Avacopan | Cytochrome P450 3A4 | enzyme |
| DB15011 | Avacopan | P-glycoprotein 1 | transporter |
| DB15011 | Avacopan | Cytochrome P450 1A2 | enzyme |
| DB15011 | Avacopan | Cytochrome P450 2B6 | enzyme |
| DB15011 | Avacopan | Cytochrome P450 2C9 | enzyme |
| DB00073 | Rituximab | B-lymphocyte antigen CD20 | target |